A patient switches her weekly GLP-1 injection from her abdomen to her arm in the middle of a frustrating plateau, and within days the scale starts moving again. She is convinced the site made the difference. Rick and Greg hear this story often in clinic, and in this episode they walk through what is actually happening physiologically versus what is more likely coincidence.

In this episode, Rick Sorensen, MD and Greg Camp, FNP break down:

• Why the abdomen, thigh, and upper arm are the three approved subcutaneous sites for semaglutide and tirzepatide (Ozempic, Wegovi, Mounjaro, Zepbound, and compounded versions)
• What the FDA label and manufacturer data actually show about drug exposure and absorption across those three sites
• Why so many people are convinced one site works better, and what plateaus and correlation versus causation have to do with it
• The decades-old insulin teaching that still shapes injection habits today, and why it does not carry over to a once-weekly GLP-1
• How to rotate within a site to avoid lipohypertrophy (that lumpy, thickened tissue) without needing to switch body parts entirely
• Injection etiquette that applies to any subcutaneous shot: clean skin, letting the alcohol dry, avoiding visible blood vessels, never reusing needles, and keeping insulin and GLP-1 injections separated
• A cautionary (and pretty funny) story about patients who spent over a month injecting air without realizing it

This episode is for education and information only. Please talk with your medical provider or pharmacist before starting, changing, or stopping any medication, weight loss program, or exercise routine, and ask for a hands-on demonstration of your injection technique if you have any questions at all.

Next up, we are tackling oral GLP-1s for anyone who would rather skip the needle altogether. Follow the show so you do not miss it, and stick around, because we have some exciting news about the Healthier Ever After brand coming very soon. If this episode helped, a quick rating or review helps other people trying to figure this out find the show.

Keywords:

GLP-1, semaglutide, tirzepatide, Ozempic, Wegovy, Mounjaro, Zepbound, GLP-1 injection sites, subcutaneous injection, weight loss injection, injection technique, lipohypertrophy, weight loss plateau, insulin vs GLP-1, GLP-1 side effects, metabolic health, weight loss medication, Healthier Ever After podcast